Logo image of ME

23ANDME HOLDING CO -CLASS A (ME) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ME - US90138Q3065 - Common Stock

0.6063 USD
-0.16 (-21.26%)
Last: 3/28/2025, 8:00:00 PM
0.5 USD
-0.11 (-17.53%)
After Hours: 3/28/2025, 8:00:00 PM
Fundamental Rating

2

Overall ME gets a fundamental rating of 2 out of 10. We evaluated ME against 102 industry peers in the Health Care Providers & Services industry. The financial health of ME is average, but there are quite some concerns on its profitability. ME is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ME has reported negative net income.
In the past year ME has reported a negative cash flow from operations.
ME had negative earnings in each of the past 5 years.
ME had a negative operating cash flow in each of the past 5 years.
ME Yearly Net Income VS EBIT VS OCF VS FCFME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

ME has a worse Return On Assets (-138.01%) than 93.64% of its industry peers.
Looking at the Return On Equity, with a value of -545.25%, ME is doing worse than 86.36% of the companies in the same industry.
Industry RankSector Rank
ROA -138.01%
ROE -545.25%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ME Yearly ROA, ROE, ROICME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ME has a better Gross Margin (52.58%) than 78.18% of its industry peers.
ME's Gross Margin has been stable in the last couple of years.
ME does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y0.67%
ME Yearly Profit, Operating, Gross MarginsME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

ME does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ME Yearly Shares OutstandingME Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 100M 200M 300M 400M
ME Yearly Total Debt VS Total AssetsME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

ME has an Altman-Z score of -13.45. This is a bad value and indicates that ME is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.45, ME is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
There is no outstanding debt for ME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.45
ROIC/WACCN/A
WACC8.71%
ME Yearly LT Debt VS Equity VS FCFME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.11 indicates that ME should not have too much problems paying its short term obligations.
ME has a Current ratio of 1.11. This is in the lower half of the industry: ME underperforms 68.18% of its industry peers.
A Quick Ratio of 0.96 indicates that ME may have some problems paying its short term obligations.
The Quick ratio of ME (0.96) is worse than 69.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.96
ME Yearly Current Assets VS Current LiabilitesME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

ME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.41%.
Looking at the last year, ME shows a very negative growth in Revenue. The Revenue has decreased by -15.83% in the last year.
The Revenue for ME have been decreasing by -13.01% on average. This is quite bad
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.53%
Revenue 1Y (TTM)-15.83%
Revenue growth 3Y-3.43%
Revenue growth 5Y-13.01%
Sales Q2Q%34.67%

3.2 Future

The Earnings Per Share is expected to grow by 25.35% on average over the next years. This is a very strong growth
ME is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.08% yearly.
EPS Next Y-329.17%
EPS Next 2Y-99.49%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue Next Year22.44%
Revenue Next 2Y19.85%
Revenue Next 3Y5.77%
Revenue Next 5Y19.08%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ME Yearly Revenue VS EstimatesME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
ME Yearly EPS VS EstimatesME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ME. In the last year negative earnings were reported.
Also next year ME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ME Price Earnings VS Forward Price EarningsME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ME Per share dataME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

A more expensive valuation may be justified as ME's earnings are expected to grow with 25.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-99.49%
EPS Next 3Y25.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ME!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

23ANDME HOLDING CO -CLASS A

NASDAQ:ME (3/28/2025, 8:00:00 PM)

After market: 0.5 -0.11 (-17.53%)

0.6063

-0.16 (-21.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners24.69%
Inst Owner Change-97.76%
Ins Owners9.89%
Ins Owner Change0%
Market Cap16.27M
Revenue(TTM)208.78M
Net Income(TTM)-382.87M
Analysts37.78
Price Target2.12 (249.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.66%
Max Revenue beat(2)1.78%
Revenue beat(4)2
Avg Revenue beat(4)-4.8%
Min Revenue beat(4)-24.62%
Max Revenue beat(4)9.3%
Revenue beat(8)4
Avg Revenue beat(8)-6%
Revenue beat(12)6
Avg Revenue beat(12)-3.09%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.08
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.73
EV/EBITDA N/A
EPS(TTM)-13.2
EYN/A
EPS(NY)-52.53
Fwd EYN/A
FCF(TTM)-6.05
FCFYN/A
OCF(TTM)-5.76
OCFYN/A
SpS7.78
BVpS2.62
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -138.01%
ROE -545.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.58%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y0.67%
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.25%
Cap/Sales 3.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 0.96
Altman-Z -13.45
F-Score4
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)39.05%
Cap/Depr(5y)93.91%
Cap/Sales(3y)4.44%
Cap/Sales(5y)8.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.53%
EPS Next Y-329.17%
EPS Next 2Y-99.49%
EPS Next 3Y25.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.83%
Revenue growth 3Y-3.43%
Revenue growth 5Y-13.01%
Sales Q2Q%34.67%
Revenue Next Year22.44%
Revenue Next 2Y19.85%
Revenue Next 3Y5.77%
Revenue Next 5Y19.08%
EBIT growth 1Y37.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.46%
EBIT Next 3Y21.64%
EBIT Next 5YN/A
FCF growth 1Y2.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.64%
OCF growth 3YN/A
OCF growth 5YN/A

23ANDME HOLDING CO -CLASS A / ME FAQ

Can you provide the ChartMill fundamental rating for 23ANDME HOLDING CO -CLASS A?

ChartMill assigns a fundamental rating of 2 / 10 to ME.


What is the valuation status for ME stock?

ChartMill assigns a valuation rating of 1 / 10 to 23ANDME HOLDING CO -CLASS A (ME). This can be considered as Overvalued.


Can you provide the profitability details for 23ANDME HOLDING CO -CLASS A?

23ANDME HOLDING CO -CLASS A (ME) has a profitability rating of 1 / 10.